Denali Therapeutics Inc.

Denali Therapeutics Inc.

DNLINYSE / NASDAQHealthcareSmall cap

$18.45+$0.25 (+1.4%)

Last close · Data as of Nov 20, 2026

Market cap
$3.2B
P/E
-6.2x
EV / EBITDA
-5.6x
Revenue
$0.00
ROCE
-53.1%

+7.5% over the last year

Denali Therapeutics Inc. price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-2.5%
3M
-26.1%
6M
-2.0%
1Y
+7.5%
5Y
-60.8%

52-week range

Day change +$0.25 (+1.4%) from $18 to $18 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in DNLI, bought on each weekday since 2021.

News & filings

What Denali Therapeutics filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 513 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 9.16 times current liabilities.
  • Revenue is too small for margins and growth rates to be read, so those points are not shown.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.

Read moreShow less

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Sector
Healthcare
Shares outstanding
156.2M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$3.2B
P/E
-6.2x
P/B
3.2x
EV / EBITDA
-5.6x
52-week high
$27.21
52-week low
$16.02

Profitability

ROE
-50.6%
ROCE
-53.1%
ROIC
-51.9%
ROA
-44.8%

Growth

Revenue
$0.00
Net profit growth, 1Y
21.2%
Free cash flow
-$422.1M

Solvency

Current ratio
9.16
Debt / Equity
0.04
Debt / Assets
0.03
CFO / Net profit
0.81
Cash / Market cap
6.4%

Revenue and net profit

Annual revenue, with net profit as the dashed line.

Denali Therapeutics Inc. revenue and net profit by fiscal year
Denali Therapeutics Inc. revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$108.5M-$326.0M
FY2023$330.5M-$145.2M
FY2024$0.00-$422.8M
FY2025$0.00-$512.5M

Cash flows

FY2025: -$412.6M from operations, -$422.1M free after investment (dashed).

Denali Therapeutics Inc. operating and free cash flow by fiscal year
Denali Therapeutics Inc. operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022-$244.7M-$262.5M
FY2023-$358.0M-$370.9M
FY2024-$347.7M-$363.6M
FY2025-$412.6M-$422.1M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$0.00
EBITDA
-$540.5M
Net profit
-$512.5M
Cash from operations
-$412.6M
Free cash flow
-$422.1M
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$0.00-$540.5M-$512.5M-$422.1M-50.6%—+21.2%

Monthly returns

Month-by-month returns of DNLI across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$1.1B
Liabilities$131.1M
Equity$1.0B
Paid-in capital$3.1B
Retained earnings-$2.1B

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; DNLI highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

EV / Sales, for the companies without earnings

Not shown (no positive earnings and no EV / Sales): Denali Therapeutics Inc., Dyne Therapeutics, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Denali Therapeutics Inc.DNLIthis company$3.2B-6.2x3.2x-50.6%-5.6x
Beam Therapeutics Inc.BEAM$3.4B-42.2x2.7x-6.5%-9.0x
Tango Therapeutics, Inc.TNGX$3.2B-31.5x9.3x-29.3%-28.7x
Haemonetics CorporationHAE$3.2B32.6x4.0x12.2%15.5x
Relay Therapeutics, Inc.RLAY$3.2B-11.5x5.6x-48.8%-10.4x
Option Care Health, Inc.OPCH$3.2B15.2x2.4x15.6%10.3x
Alignment Healthcare, Inc.ALHC$3.1B—17.4x-0.4%62.7x
Dyne Therapeutics, Inc.DYN$3.0B-6.8x3.1x-45.9%-5.3x
Warby Parker Inc.WRBY$3.0B1803.7x8.0x0.4%64.7x
Peer median—-6.8x4.8x-3.4%2.5x

Year-to-date ROI

DNLI since 1 January, against earlier years.

Historical volatility

DNLI's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Denali Therapeutics Inc. operating margin by fiscal year
Denali Therapeutics Inc. operating margin by fiscal year
DateOperating margin
FY2022-314.2%
FY2023-59.5%
FY2024—
FY2025—
LineFY2025
Operating expensesOperating Expense$555.3M
Research and developmentResearch And Development$418.8M
Total expensesTotal Expenses$555.3M
Pretax incomePretax Income-$512.4M

Learn while you research

Academy chapters picked for Denali Therapeutics Inc. and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →